RXi Pharmaceuticals Set to Join Russell Microcap Index
MARLBOROUGH, Mass., June 25, 2014
MARLBOROUGH, Mass., June 25, 2014 /PRNewswire/ --RXi Pharmaceuticals
Corporation (NASDAQ: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced the Company is
set to join the Russell Microcap^®Index when Russell Investments
reconstitutes its comprehensive set of U.S. and global equity indexes on June
27, 2014, according to a preliminary list of additions posted June 13, 2014 on
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Membership in the Russell Microcap Index, which remains in place for one year,
means automatic inclusion in the appropriate growth and value style indexes.
Russell determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes.
"We are pleased with the anticipated inclusion in the Russell Microcap Index,"
said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "This
listing provides another positive step forward, for our Company and its
shareholders, increasing visibility and awareness amongst institutional
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
Russell calculates more than 700,000 benchmarks daily covering approximately
98 percent of the investable market globally, 80 countries and more than
10,000 securities.Approximately $5.2 trillion in assets are benchmarked to
the Russell Indexes.
Annual reconstitution of Russell Indexes captures the 4,000 largest U.S.
stocks as of the end of May, ranking them by total market capitalization to
create the Russell 3000^® Index and Russell Microcap Index. These investment
tools originated from Russell's multi-manager investment business in the early
1980s when the company saw the need for a more objective, market-driven set of
benchmarks in order to evaluate outside investment managers.
Russell Investments (Russell) is a global asset manager and one of only a few
firms that offers actively managed multi-asset portfolios and services that
include advice, investments and implementation. Russell stands with
institutional investors, financial advisors and individuals working with their
advisors—using the firm's core capabilities that extend across capital market
insights, manager research, portfolio construction, portfolio implementation
and indexes to help each achieve their desired investment outcomes.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company
focused on discovering, developing and commercializing innovative therapies
based on its proprietary, self-delivering RNAi (sd-rxRNA^®) platform.
Therapeutics that use RNA interference, or "RNAi," have greatpromise because
of their ability to down-regulate the expression of specific genes that may be
over-expressed in disease conditions. Building on the pioneering work of
scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109,
entered into human clinical trials in June 2012 and is currently being
evaluated in Phase 2 clinical trials. RXI‑109 targets connective tissue
growth factor (CTGF) to reduce dermal scarring (fibrosis).RXi's sd‑rxRNA
oligonucleotides are designed for therapeutic use and have drug-like
properties, such as high potency, target specificity, serum stability, reduced
immune response activation, and efficient cellular uptake. These hybrid
oligonucleotide molecules combine the beneficial properties of conventional
RNAi and antisense technologies. This allows sd‑rxRNAs to achieve efficient
cellular uptake and potent, long-lasting intracellular activity. For more
information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks and uncertainties: the risk
that we may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed, risks related
to the development and commercialization of products by our competitors, the
risk related to our ability to control the timing and terms of collaborations
with third parties, and the possibility that other companies or organizations
may assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.
SOURCE RXi Pharmaceuticals Corporation
Press spacebar to pause and continue. Press esc to stop.